BIOMAT Database Logo BIOMAT Database Logo

Study on the design, synthesis and structure-activity relationships of new thiosemicarbazone compounds as tyrosinase inhibitors. 2017

Senchuan Song, and Ao You, and Zhiyong Chen, and Guoxun Zhu, and Huan Wen, and Huacan Song, and Wei Yi
School of Chemical Engineering and Technology, Sun Yat-sen University, 135 Xin Gang West Road, Guangzhou 510275, PR China; China National Analysis Center, Guangzhou 510070, PR China.

52 Structure-based thiosemicarbazone compounds bearing various substituted-lipophilic part, including substituted-benzaldehyde, substituted-phenylalkan-1-one and their biphenyl-type thiosemicarbazone analogs, were designed, synthesized and evaluated as new tyrosinase inhibitors. The results demonstrated that 22 compounds have potent inhibitory activities against tyrosinase with the IC50 value of lower than 1.0 μM. On the basis of the obtained experimental data, the structure-activity relationships (SARs) were rationally derived. Besides, the inhibition mechanism and the inhibitory kinetics of selected compounds 3d and 6e were investigated, revealing that such type of compounds were belonged to the reversible and competitive tyrosinase inhibitors. To verify the safety of these developed thiosemicarbazone compounds, four randomly selected compounds 3d, 4e, 6a and 9a were also tested in 293T cell line for the evaluation of the cytotoxicity. Interestingly, all these compounds almost did not perform any toxicity to 293T cells even at a high concentration of 1000 μmol/L. Taken together, these results suggested that such compounds could serve as the highly efficient and more safe candidates for the treatment of tyrosinase-related disorders.

UI MeSH Term Description Entries
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013882 Thiosemicarbazones Thiosemicarbazone
D014442 Monophenol Monooxygenase An enzyme of the oxidoreductase class that catalyzes the reaction between L-tyrosine, L-dopa, and oxygen to yield L-dopa, dopaquinone, and water. It is a copper protein that acts also on catechols, catalyzing some of the same reactions as CATECHOL OXIDASE. EC 1.14.18.1. Dopa Oxidase,Phenoloxidase,Tyrosinase,Cresolase,Phenol Oxidase,Phenoloxidase A,Phenoloxidase B,Monooxygenase, Monophenol,Oxidase, Dopa,Oxidase, Phenol
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular
D057809 HEK293 Cells A cell line generated from human embryonic kidney cells that were transformed with human adenovirus type 5. 293T Cells,HEK 293 Cell Line,HEK 293 Cells,Human Embryonic Kidney Cell Line 293,Human Kidney Cell Line 293,293 Cell, HEK,293 Cells, HEK,293T Cell,Cell, 293T,Cell, HEK 293,Cell, HEK293,Cells, 293T,Cells, HEK 293,Cells, HEK293,HEK 293 Cell,HEK293 Cell

Related Publications

Senchuan Song, and Ao You, and Zhiyong Chen, and Guoxun Zhu, and Huan Wen, and Huacan Song, and Wei Yi
Synthesis, structure-activity relationships and biological activity of new isatin derivatives as tyrosinase inhibitors.
January 2014, Current topics in medicinal chemistry,
Senchuan Song, and Ao You, and Zhiyong Chen, and Guoxun Zhu, and Huan Wen, and Huacan Song, and Wei Yi
Oxazolones: new tyrosinase inhibitors; synthesis and their structure-activity relationships.
September 2006, Bioorganic & medicinal chemistry,
Senchuan Song, and Ao You, and Zhiyong Chen, and Guoxun Zhu, and Huan Wen, and Huacan Song, and Wei Yi
Synthesis of novel compounds as new potent tyrosinase inhibitors.
January 2013, BioMed research international,
Senchuan Song, and Ao You, and Zhiyong Chen, and Guoxun Zhu, and Huan Wen, and Huacan Song, and Wei Yi
Design, synthesis and structure-activity relationships of new phosphinate inhibitors of MurD.
January 2006, Bioorganic & medicinal chemistry letters,
Senchuan Song, and Ao You, and Zhiyong Chen, and Guoxun Zhu, and Huan Wen, and Huacan Song, and Wei Yi
A new phenolic series of indenopyridinone as topoisomerase inhibitors: Design, synthesis, and structure-activity relationships.
October 2018, Bioorganic & medicinal chemistry,
Senchuan Song, and Ao You, and Zhiyong Chen, and Guoxun Zhu, and Huan Wen, and Huacan Song, and Wei Yi
Design, synthesis, and structure-activity relationships of azolylmethylpyrroloquinolines as nonsteroidal aromatase inhibitors.
October 2013, Journal of medicinal chemistry,
Senchuan Song, and Ao You, and Zhiyong Chen, and Guoxun Zhu, and Huan Wen, and Huacan Song, and Wei Yi
Design, synthesis and structure activity relationships of spirocyclic compounds as potent CCR1 antagonists.
June 2013, Bioorganic & medicinal chemistry letters,
Senchuan Song, and Ao You, and Zhiyong Chen, and Guoxun Zhu, and Huan Wen, and Huacan Song, and Wei Yi
Design, synthesis, and structure-activity relationships of pyrazole derivatives as potential FabH inhibitors.
August 2010, Bioorganic & medicinal chemistry letters,
Senchuan Song, and Ao You, and Zhiyong Chen, and Guoxun Zhu, and Huan Wen, and Huacan Song, and Wei Yi
Design, synthesis, and structure-activity relationships of pyridoquinazolinecarboxamides as RNA polymerase I inhibitors.
June 2014, Journal of medicinal chemistry,
Senchuan Song, and Ao You, and Zhiyong Chen, and Guoxun Zhu, and Huan Wen, and Huacan Song, and Wei Yi
New phenolic cinnamic acid derivatives as selective COX-2 inhibitors. Design, synthesis, biological activity and structure-activity relationships.
October 2019, Bioorganic chemistry,
Copied contents to your clipboard!